<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:51:45 -0700</creation_date>
  <update_date>2013-05-27 11:12:13 -0600</update_date>
  <accession>HMDBP00790</accession>
  <secondary_accessions>
    <accession>6070</accession>
    <accession>HMDBP04883</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
  </synonyms>
  <gene_name>DHFR</gene_name>
  <general_function>Involved in dihydrofolate reductase activity</general_function>
  <specific_function>Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
</specific_function>
  <pathways>
    <pathway>
      <name>tetrahydrofolate biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>One carbon pool by folate</name>
      <smpdb_id/>
      <kegg_map_id>map00670</kegg_map_id>
    </pathway>
    <pathway>
      <name>Folate biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00790</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00121</accession>
      <name>Folic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01846</accession>
      <name>Tetrahydrofolic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01056</accession>
      <name>Dihydrofolic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00217</accession>
      <name>NADP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00221</accession>
      <name>NADPH</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00038</accession>
      <name>Dihydrobiopterin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14350</accession>
      <name>Pyrimethamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14583</accession>
      <name>Trimethoprim</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14703</accession>
      <name>Methotrexate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14780</accession>
      <name>Pemetrexed</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15263</accession>
      <name>Proguanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15288</accession>
      <name>Trimetrexate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00902</accession>
      <name>NAD</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01487</accession>
      <name>NADH</name>
    </metabolite>
    <metabolite>
      <accession>HMDB59597</accession>
      <name>Hydrogen Ion</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nadp or nadph binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on the ch-nh group of donors</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on the ch-nh group of donors, nad or nadp as acceptor</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>dihydrofolate reductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside, nucleotide and nucleic acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside and nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleoside phosphate metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleotide biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular amino acid and derivative metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular amino acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>serine family amino acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>glycine metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>glycine biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nucleoplasm</description>
      <go_id>GO:0005654</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>dihydrofolate reductase activity</description>
      <go_id>GO:0004146</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>drug binding</description>
      <go_id>GO:0008144</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>mRNA binding</description>
      <go_id>GO:0003729</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>NADP binding</description>
      <go_id>GO:0050661</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>folic acid metabolic process</description>
      <go_id>GO:0046655</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>glycine biosynthetic process</description>
      <go_id>GO:0006545</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>nitric oxide metabolic process</description>
      <go_id>GO:0046209</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>nucleotide biosynthetic process</description>
      <go_id>GO:0009165</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>one-carbon metabolic process</description>
      <go_id>GO:0006730</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of nitric-oxide synthase activity</description>
      <go_id>GO:0050999</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of transcription involved in G1/S phase of mitotic cell cycle</description>
      <go_id>GO:0000083</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to methotrexate</description>
      <go_id>GO:0031427</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>tetrahydrofolate biosynthetic process</description>
      <go_id>GO:0046654</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>tetrahydrofolate metabolic process</description>
      <go_id>GO:0046653</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>5</chromosome_location>
    <locus>5q11.2-q13.2</locus>
    <gene_sequence>&gt;564 bp
ATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAAC
GGGGACCTGCCCTGGCCACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACA
ACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCC
ATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTC
AAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTT
ACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCT
GTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATG
CAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTG
CCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTT
GAAGTATATGAGAAGAATGATTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>187</residue_number>
    <molecular_weight>21452.61</molecular_weight>
    <theoretical_pi>7.42</theoretical_pi>
    <pfams>
      <pfam>
        <name>DHFR_1</name>
        <pfam_id>PF00186</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Dihydrofolate reductase
MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFS
IPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSS
VYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKF
EVYEKND</protein_sequence>
  </protein_properties>
  <genbank_protein_id>182724</genbank_protein_id>
  <uniprot_id>P00374</uniprot_id>
  <uniprot_name>DYR_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1BOZ</pdb_id>
    <pdb_id>1DHF</pdb_id>
    <pdb_id>1DLR</pdb_id>
    <pdb_id>1DLS</pdb_id>
    <pdb_id>1DRF</pdb_id>
    <pdb_id>1HFP</pdb_id>
    <pdb_id>1HFQ</pdb_id>
    <pdb_id>1HFR</pdb_id>
    <pdb_id>1KMS</pdb_id>
    <pdb_id>1KMV</pdb_id>
    <pdb_id>1MVS</pdb_id>
    <pdb_id>1MVT</pdb_id>
    <pdb_id>1OHJ</pdb_id>
    <pdb_id>1OHK</pdb_id>
    <pdb_id>1PD8</pdb_id>
    <pdb_id>1PD9</pdb_id>
    <pdb_id>1PDB</pdb_id>
    <pdb_id>1S3U</pdb_id>
    <pdb_id>1S3V</pdb_id>
    <pdb_id>1S3W</pdb_id>
    <pdb_id>1U71</pdb_id>
    <pdb_id>1U72</pdb_id>
    <pdb_id>1YHO</pdb_id>
    <pdb_id>2C2S</pdb_id>
    <pdb_id>2C2T</pdb_id>
    <pdb_id>2DHF</pdb_id>
    <pdb_id>2W3A</pdb_id>
    <pdb_id>2W3B</pdb_id>
    <pdb_id>2W3M</pdb_id>
    <pdb_id>3EIG</pdb_id>
    <pdb_id>3F8Y</pdb_id>
    <pdb_id>3F8Z</pdb_id>
    <pdb_id>3F91</pdb_id>
    <pdb_id>3FS6</pdb_id>
    <pdb_id>3GHC</pdb_id>
    <pdb_id>3GHV</pdb_id>
    <pdb_id>3GHW</pdb_id>
    <pdb_id>3GI2</pdb_id>
    <pdb_id>3GYF</pdb_id>
    <pdb_id>3L3R</pdb_id>
    <pdb_id>3N0H</pdb_id>
    <pdb_id>3NTZ</pdb_id>
    <pdb_id>3NU0</pdb_id>
    <pdb_id>3NXO</pdb_id>
    <pdb_id>3NXR</pdb_id>
    <pdb_id>3NXT</pdb_id>
    <pdb_id>3NXV</pdb_id>
    <pdb_id>3NXX</pdb_id>
    <pdb_id>3NXY</pdb_id>
    <pdb_id>3NZD</pdb_id>
    <pdb_id>3OAF</pdb_id>
    <pdb_id>3S3V</pdb_id>
    <pdb_id>3S7A</pdb_id>
    <pdb_id>4DDR</pdb_id>
  </pdb_ids>
  <genbank_gene_id>J00140</genbank_gene_id>
  <genecard_id>DHFR</genecard_id>
  <geneatlas_id>DHFR</geneatlas_id>
  <hgnc_id>HGNC:2861</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J, Nienhuis AW: The functional human dihydrofolate reductase gene.  J Biol Chem. 1984 Mar 25;259(6):3933-43.</reference_text>
      <pubmed_id>6323448</pubmed_id>
    </reference>
    <reference>
      <reference_text>Masters JN, Attardi G: The nucleotide sequence of the cDNA coding for the human dihydrofolic acid reductase. Gene. 1983 Jan-Feb;21(1-2):59-63.</reference_text>
      <pubmed_id>6687716</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yang JK, Masters JN, Attardi G: Human dihydrofolate reductase gene organization. Extensive conservation of the G + C-rich 5' non-coding sequence and strong intron size divergence from homologous mammalian genes. J Mol Biol. 1984 Jun 25;176(2):169-87.</reference_text>
      <pubmed_id>6235374</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Oefner C, D'Arcy A, Winkler FK: Crystal structure of human dihydrofolate reductase complexed with folate.  Eur J Biochem. 1988 Jun 1;174(2):377-85.</reference_text>
      <pubmed_id>3383852</pubmed_id>
    </reference>
    <reference>
      <reference_text>Davies JF 2nd, Delcamp TJ, Prendergast NJ, Ashford VA, Freisheim JH, Kraut J: Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry. 1990 Oct 9;29(40):9467-79.</reference_text>
      <pubmed_id>2248959</pubmed_id>
    </reference>
    <reference>
      <reference_text>Stockman BJ, Nirmala NR, Wagner G, Delcamp TJ, DeYarman MT, Freisheim JH: Sequence-specific 1H and 15N resonance assignments for human dihydrofolate reductase in solution. Biochemistry. 1992 Jan 14;31(1):218-29.</reference_text>
      <pubmed_id>1731871</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lewis WS, Cody V, Galitsky N, Luft JR, Pangborn W, Chunduru SK, Spencer HT, Appleman JR, Blakley RL: Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J Biol Chem. 1995 Mar 10;270(10):5057-64.</reference_text>
      <pubmed_id>7890613</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Blakley RL: Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry. 1997 Nov 11;36(45):13897-903.</reference_text>
      <pubmed_id>9374868</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gangjee A, Vidwans AP, Vasudevan A, Queener SF, Kisliuk RL, Cody V, Li R, Galitsky N, Luft JR, Pangborn W: Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents. J Med Chem. 1998 Aug 27;41(18):3426-34.</reference_text>
      <pubmed_id>9719595</pubmed_id>
    </reference>
    <reference>
      <reference_text>Klon AE, Heroux A, Ross LJ, Pathak V, Johnson CA, Piper JR, Borhani DW: Atomic structures of human dihydrofolate reductase complexed with NADPH and two lipophilic antifolates at 1.09 a and 1.05 a resolution. J Mol Biol. 2002 Jul 12;320(3):677-93.</reference_text>
      <pubmed_id>12096917</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cody V, Galitsky N, Luft JR, Pangborn W, Gangjee A: Analysis of two polymorphic forms of a pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolate binary complex with human dihydrofolate reductase. Acta Crystallogr D Biol Crystallogr. 2003 Apr;59(Pt 4):654-61. Epub 2003       Mar 25.</reference_text>
      <pubmed_id>12657784</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cody V, Luft JR, Pangborn W, Gangjee A: Analysis of three crystal structure determinations of a 5-methyl-6-N-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase. Acta Crystallogr D Biol Crystallogr. 2003 Sep;59(Pt 9):1603-9. Epub 2003       Aug 19.</reference_text>
      <pubmed_id>12925791</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cody V, Luft JR, Pangborn W, Gangjee A, Queener SF: Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry. Acta Crystallogr D Biol Crystallogr. 2004 Apr;60(Pt 4):646-55. Epub 2004       Mar 23.</reference_text>
      <pubmed_id>15039552</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cody V, Luft JR, Pangborn W: Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH. Acta Crystallogr D Biol Crystallogr. 2005 Feb;61(Pt 2):147-55. Epub 2005       Jan 19.</reference_text>
      <pubmed_id>15681865</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kovalevskaya NV, Smurnyy YD, Polshakov VI, Birdsall B, Bradbury AF, Frenkiel T, Feeney J: Solution structure of human dihydrofolate reductase in its complex with trimethoprim and NADPH. J Biomol NMR. 2005 Sep;33(1):69-72.</reference_text>
      <pubmed_id>16222560</pubmed_id>
    </reference>
    <reference>
      <reference_text>Reynolds RC, Campbell SR, Fairchild RG, Kisliuk RL, Micca PL, Queener SF, Riordan JM, Sedwick WD, Waud WR, Leung AK, Dixon RW, Suling WJ, Borhani DW: Novel boron-containing, nonclassical antifolates: synthesis and preliminary biological and structural evaluation. J Med Chem. 2007 Jul 12;50(14):3283-9. Epub 2007 Jun 15.</reference_text>
      <pubmed_id>17569517</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cody V, Pace J, Makin J, Piraino J, Queener SF, Rosowsky A: Correlations of inhibitor kinetics for Pneumocystis jirovecii and human dihydrofolate reductase with structural data for human active site mutant enzyme complexes. Biochemistry. 2009 Mar 3;48(8):1702-11.</reference_text>
      <pubmed_id>19196009</pubmed_id>
    </reference>
    <reference>
      <reference_text>Volpato JP, Yachnin BJ, Blanchet J, Guerrero V, Poulin L, Fossati E, Berghuis AM, Pelletier JN: Multiple conformers in active site of human dihydrofolate reductase F31R/Q35E double mutant suggest structural basis for methotrexate resistance. J Biol Chem. 2009 Jul 24;284(30):20079-89. Epub 2009 May 28.</reference_text>
      <pubmed_id>19478082</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gangjee A, Li W, Kisliuk RL, Cody V, Pace J, Piraino J, Makin J: Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents. J Med Chem. 2009 Aug 13;52(15):4892-902.</reference_text>
      <pubmed_id>19719239</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Dihydrobiopterin</name>
        <accession>HMDB00038</accession>
      </metabolite>
      <reference>
        <reference_text>Bowers SW, Duch DS: In vivo measurement of dihydrofolate reductase and its inhibition by antifolates. Anal Biochem. 1988 Jul;172(1):169-75.</reference_text>
        <pubmed_id>3189762</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyrimethamine</name>
        <accession>HMDB14350</accession>
      </metabolite>
      <reference>
        <reference_text>Rastelli G, Pacchioni S, Parenti MD: Structure of Plasmodium vivax dihydrofolate reductase determined by homology modeling and molecular dynamics refinement. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3257-60.</reference_text>
        <pubmed_id>12951104</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyrimethamine</name>
        <accession>HMDB14350</accession>
      </metabolite>
      <reference>
        <reference_text>Fidock DA, Wellems TE: Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.</reference_text>
        <pubmed_id>9380737</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyrimethamine</name>
        <accession>HMDB14350</accession>
      </metabolite>
      <reference>
        <reference_text>Wooden JM, Hartwell LH, Vasquez B, Sibley CH: Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mol Biochem Parasitol. 1997 Mar;85(1):25-40.</reference_text>
        <pubmed_id>9108546</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyrimethamine</name>
        <accession>HMDB14350</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Laskowska E, Kuczynska-Wisnik D, Bak M, Lipinska B: Trimethoprim induces heat shock proteins and protein aggregation in E. coli cells. Curr Microbiol. 2003 Oct;47(4):286-9.</reference_text>
        <pubmed_id>14629008</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Floris-Moore MA, Amodio-Groton MI, Catalano MT: Adverse reactions to trimethoprim/sulfamethoxazole in AIDS.  Ann Pharmacother. 2003 Dec;37(12):1810-3.</reference_text>
        <pubmed_id>14632594</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Rosowsky A, Fu H, Chan DC, Queener SF: Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridine s as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase. J Med Chem. 2004 May 6;47(10):2475-85.</reference_text>
        <pubmed_id>15115391</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM: Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004 Nov;48(11):4301-5.</reference_text>
        <pubmed_id>15504856</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Barrow EW, Bourne PC, Barrow WW: Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim. Antimicrob Agents Chemother. 2004 Dec;48(12):4643-9.</reference_text>
        <pubmed_id>15561838</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Al-Rashood ST, Aboldahab IA, Nagi MN, Abouzeid LA, Abdel-Aziz AA, Abdel-Hamide SG, Youssef KM, Al-Obaid AM, El-Subbagh HI: Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. Bioorg Med Chem. 2006 Dec 15;14(24):8608-21. Epub 2006 Sep 12.</reference_text>
        <pubmed_id>16971132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Assaraf YG: Molecular basis of antifolate resistance.  Cancer Metastasis Rev. 2007 Mar;26(1):153-81.</reference_text>
        <pubmed_id>17333344</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Bennett B, Langan P, Coates L, Mustyakimov M, Schoenborn B, Howell EE, Dealwis C: Neutron diffraction studies of Escherichia coli dihydrofolate reductase complexed with methotrexate. Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18493-8. Epub 2006 Nov 27.</reference_text>
        <pubmed_id>17130456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Totani K, Matsuo I, Ihara Y, Ito Y: High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates. Bioorg Med Chem. 2006 Aug 1;14(15):5220-9. Epub 2006 May 2.</reference_text>
        <pubmed_id>16647263</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, Hatakeyama M, Yamaguchi Y, Takahashi T, Kizaki M, Handa H: A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol. 2006 Nov;70(5):1832-9. Epub 2006 Aug 25.</reference_text>
        <pubmed_id>16936229</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate.  Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24.</reference_text>
        <pubmed_id>17586865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73.</reference_text>
        <pubmed_id>11524555</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Norman P: Pemetrexed disodium (Eli Lilly).  Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22.</reference_text>
        <pubmed_id>11763166</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, Noordhuis P, Bunni MA, Rosowsky A, Schornagel JH, Pinedo HM, Jansen G: Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol. 2002 Jan 15;63(2):105-15.</reference_text>
        <pubmed_id>11841783</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14.</reference_text>
        <pubmed_id>11848474</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Adjei AA: Pemetrexed in the treatment of selected solid tumors.  Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3.</reference_text>
        <pubmed_id>12023793</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer.  Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7.</reference_text>
        <pubmed_id>11252887</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55.</reference_text>
        <pubmed_id>11531245</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.  Lung Cancer. 2001 Dec;34 Suppl 4:S103-5.</reference_text>
        <pubmed_id>11742712</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.  Clin Lung Cancer. 2003 Jul;5(1):21-7.</reference_text>
        <pubmed_id>14596699</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28.</reference_text>
        <pubmed_id>15795320</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Kindler HL: Pemetrexed in pancreatic cancer.  Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53.</reference_text>
        <pubmed_id>12571811</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Proguanil</name>
        <accession>HMDB15263</accession>
      </metabolite>
      <reference>
        <reference_text>Kaneko A, Bergqvist Y, Takechi M, Kalkoa M, Kaneko O, Kobayakawa T, Ishizaki T, Bjorkman A: Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J Infect Dis. 1999 Apr;179(4):974-9.</reference_text>
        <pubmed_id>10068594</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Proguanil</name>
        <accession>HMDB15263</accession>
      </metabolite>
      <reference>
        <reference_text>Vasconcelos KF, Plowe CV, Fontes CJ, Kyle D, Wirth DF, Pereira da Silva LH, Zalis MG: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Mem Inst Oswaldo Cruz. 2000 Sep-Oct;95(5):721-8.</reference_text>
        <pubmed_id>10998224</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Proguanil</name>
        <accession>HMDB15263</accession>
      </metabolite>
      <reference>
        <reference_text>Tahar R, de Pecoulas PE, Basco LK, Chiadmi M, Mazabraud A: Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli. Mol Biochem Parasitol. 2001 Apr 6;113(2):241-9.</reference_text>
        <pubmed_id>11295178</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Proguanil</name>
        <accession>HMDB15263</accession>
      </metabolite>
      <reference>
        <reference_text>Durand R, Jafari S, Bouchaud O, Ralaimazava P, Keundjian A, Le Bras J: Plasmodium falciparum: pfcrt and DHFR mutations are associated with failure of chloroquine plus proguanil prophylaxis in travelers. J Infect Dis. 2001 Dec 15;184(12):1633-4.</reference_text>
        <pubmed_id>11740746</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Proguanil</name>
        <accession>HMDB15263</accession>
      </metabolite>
      <reference>
        <reference_text>Le Bras J, Durand R: The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum.  Fundam Clin Pharmacol. 2003 Apr;17(2):147-53.</reference_text>
        <pubmed_id>12667224</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Proguanil</name>
        <accession>HMDB15263</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimetrexate</name>
        <accession>HMDB15288</accession>
      </metabolite>
      <reference>
        <reference_text>Bertino JR, Zhao SC, Mineishi S, Ercikan-Abali EA, Banerjee D: Use of variants of dihydrofolate reductase in gene transfer to produce resistance to methotrexate and trimetrexate. Prog Exp Tumor Res. 1999;36:82-94.</reference_text>
        <pubmed_id>10386066</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimetrexate</name>
        <accession>HMDB15288</accession>
      </metabolite>
      <reference>
        <reference_text>Graffner-Nordberg M, Kolmodin K, Aqvist J, Queener SF, Hallberg A: Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. J Med Chem. 2001 Jul 19;44(15):2391-402.</reference_text>
        <pubmed_id>11448221</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimetrexate</name>
        <accession>HMDB15288</accession>
      </metabolite>
      <reference>
        <reference_text>Warlick CA, Diers MD, Wagner JE, McIvor RS: In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. J Pharmacol Exp Ther. 2002 Jan;300(1):50-6.</reference_text>
        <pubmed_id>11752096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimetrexate</name>
        <accession>HMDB15288</accession>
      </metabolite>
      <reference>
        <reference_text>Zhu WY, Bunni M, Priest DG, DiCapua JL, Dressler JM, Chen Z, Melera PW: Severe folate restriction results in depletion of and alteration in the composition of the intracellular folate pool, moderate sensitization to methotrexate and trimetrexate, upregulation of endogenous DHFR activity, and overexpression of metallothionein II and folate receptor alpha that, upon folate repletion, confer drug resistance to CHL cells. J Exp Ther Oncol. 2002 Sep-Oct;2(5):264-77.</reference_text>
        <pubmed_id>12416030</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimetrexate</name>
        <accession>HMDB15288</accession>
      </metabolite>
      <reference>
        <reference_text>Sweeney CL, Frandsen JL, Verfaillie CM, McIvor RS: Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase. Cancer Res. 2003 Mar 15;63(6):1304-10.</reference_text>
        <pubmed_id>12649191</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimetrexate</name>
        <accession>HMDB15288</accession>
      </metabolite>
      <reference>
        <reference_text>Polshakov VI, Birdsall B, Frenkiel TA, Gargaro AR, Feeney J: Structure and dynamics in solution of the complex of Lactobacillus casei dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate. Protein Sci. 1999 Mar;8(3):467-81.</reference_text>
        <pubmed_id>10091649</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimetrexate</name>
        <accession>HMDB15288</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
